雷珠单抗在新生血管性青光眼治疗中的有效性与安全性分析

Analysis of the effectiveness and safety of leazuzumab in treatment of neovascular glaucoma

目的探讨雷珠单抗联合EX-PRESS青光眼引流植入术治疗新生血管性青光眼（NVG）的有效性和安全性。方法选取2013年1月～2016年5月陕西省杨陵区妇幼保健计划生育服务中收治的60例（74眼）NVG患者分为2组，对照组采用贝伐单抗联手术进行治疗；观察组41眼实施雷珠单抗联合手术治疗。对比2组术前、术后眼压、抗青光眼用药类数及虹膜面新生血管消退情况。结果与对照组比，观察组治疗后虹膜表面新生血管彻底消退时间明显缩短，彻底消退率明显升高；2组1年内眼压均明显降低，抗青光眼类药物类数明显较少，且观察组术后1～7d内眼压明显低于对照组（P＜0.05）。结论雷珠单抗联合EX-PRESS青光眼引流植入术可有效促进新生血管彻底消退，短期内降眼压疗效明显优于贝伐单抗。

Objective To investigate the efficacy and safety of leazuzumab combined with EX-PRESS glaucoma drainage in the treatment of neovascular glaucoma(NVG).Methods60patients(74eyes)with NVG were divided into two groups.The control group was treated by bevacizumab combined with surgery.The observation group was treated by leazuzumab combined with surgery.The intraocular pressure,the number of anti-glaucoma medication and revascularization of revascularization of iris surface were observed before and after operation.Results Compared with the control group,the extinction time of regression of neovascularization in the observation group was significantly shorter,and rate of complete regression of neovascularization was significantly higher after treatment;the intraocular pressure of the two groups was significantly lower within one year after surgery,the number of anti-glaucoma medication was significantly reduced,and the intraocular pressure of the observation group was significantly higher than that in the control group within seven days after surgery(P<0.05).Conclusion Leazuzumab combined with EX-PRESS glaucoma drainage implantation can effectively promote the neonatal blood vessels to completely dissipate,and is better than bevacizumab in shortterm reduction of intraocular pressure.